Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash flow from operating activities:
Net loss	$ (1,828,080)	$ (4,133,432)
Adjustments to reconcile net loss to net cash used in operating activities:
Recognition of credit loss on notes receivable	795,353
Accrued interest revenue	(42,746)
Loss on equity method investment	439,637	960,508
Gain on revaluation of equity method investment	(6,164,260)
Depreciation and amortization	259,362	41,062
Vesting expense for stock options	1,644,220	460,368
Amortization of debt discount	1,068,256
Loss on valuation of equity-linked instruments	231,348
Gain on revaluation of cash advances to Helomics	(1,222,244)
Changes in assets and liabilities:
Accounts receivable	141,325	(177,828)
Inventories	(55,665)	20,385
Prepaid expense and other assets	66,989	14,490
Accounts payable	718,483	25,126
Accrued expenses	(104,114)	(329,889)
Deferred revenue	6,641	11,679
Net cash used in operating activities	(4,045,495)	(3,107,531)
Cash flow from investing activities:
Redemption of certificates of deposit		244,971
Advance on notes receivable	(975,000)	(42,524)
Cash received from notes receivable	154,418
Cash received in Helomics Acquisition	248,102
Purchase of fixed assets		(129,990)
Acquisition of intangibles	(8,433)	(27,524)
Net cash (used in) provided by investing activities:	(580,913)	44,933
Cash flow from financing activities:
Extinguishment of convertible debt	(220,241)
Proceeds from debt issuance	1,525,000
Proceeds from exercise of warrants into common stock	5,786	341,169
Proceeds from issuance of Series E convertible preferred stock	743,560
Issuance of common stock	2,479,708	2,959,509
Net cash provided by financing activities	4,533,813	3,300,678
Net decrease in cash and cash equivalents	(92,595)	238,080
Cash at beginning of period	162,152	766,189
Cash at end of period	69,557	1,004,269
Non-cash transactions:
Bridge loan conversion into common stock	238,573
Forbearance settlement bridge loan	503,009
Value of warrants issued	32,215
Consideration given for acquisition of Helomics	26,711,791	1,542,250
Conversion of preferred stock to common stock		$ 6,479